QUIZ: Treatment and Management of Skin Cancer

Last week, we invited you to participate in the third of our weekly polls this month for Skin Cancer Awareness Month. We asked questions related to characteristic dermoscopic features, the "blue-white veil" in dermoscopy, dermoscopic findings suggestive of seborrheic keratosis, structures commonly seen in basal cell carcinoma, and the "3-point checklist" to differentiate between benign and malignant lesions.

If you have not yet taken our quiz, feel free to do so here. Later in the week, we also provided a rundown of the answers to the quiz along with additional information about dermoscopy and melanoma detection. Review your responses here.

This week, we have put together a 5-question quiz testing your knowledge of the treatment and management of skin cancer.

At the end of the week, we will provide a rundown of answers to the quiz with additional resources and information for each question.

Have an idea for a quiz? Feel free to share your insights and knowledge of rosacea by emailing our team at DTEditor@mmhgroup.com.

Dermatology Times invites you to join us in advancing understanding, promoting dialogue, and ultimately improving outcomes for individuals living with skin cancer. Stay tuned for our weekly quizzes, and let's work together to make a difference this Skin Cancer Awareness Month.

Review recent Dermatology Times skin cancer news and content:

Reviewing the Skin Cancer Pipeline: A Look at the Last 10 Years

In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.

More Clinicians are Needed in the Fight Against Skin Cancer

Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.

Mohs Surgical Training Around the World: Need for Standardized Database

While MMS is recognized as the gold standard for skin cancer treatment, numerous challenges still hinder widespread adoption and practice.

FDA Updates PDUFA Date of Subcutaneous Nivolumab

The new action date is December 29, 2024.

QUIZ RECAP: Dermoscopy and Melanoma Detection

Earlier this week, we shared our third Skin Cancer Awareness Month quiz. Review the answers and your responses below.